Last $4.76 USD
Change Today -0.01 / -0.21%
Volume 28.3K
ALIM On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:37 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

alimera sciences inc (ALIM) Snapshot

Open
$4.78
Previous Close
$4.77
Day High
$4.79
Day Low
$4.75
52 Week High
01/17/14 - $8.44
52 Week Low
11/14/13 - $1.76
Market Cap
204.6M
Average Volume 10 Days
217.5K
EPS TTM
$-0.84
Shares Outstanding
43.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALIMERA SCIENCES INC (ALIM)

alimera sciences inc (ALIM) Related Businessweek News

No Related Businessweek News Found

alimera sciences inc (ALIM) Details

Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company’s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that uses the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

31 Employees
Last Reported Date: 03/7/14
Founded in 2003

alimera sciences inc (ALIM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $505.7K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $352.8K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $333.4K
Compensation as of Fiscal Year 2013.

alimera sciences inc (ALIM) Key Developments

Alimera Sciences, Inc. Receives $25 Million Advance from Hercules Technology Growth Capital

Alimera Sciences, Inc. announced that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. The payment is the second and final advance under the Loan and Security Agreement that Alimera's subsidiary in the United Kingdom, Alimera Sciences Limited, entered into with Hercules in April of this year. Receipt of the $25 million was conditional on the approval, on or before October 31, 2014, of ILUVIEN by the U.S. Food and Drug Administration (FDA). Alimera will use the advance to fund a $25 million milestone payment owed to the licensor of certain intellectual properly as a result of the recent FDA approval of ILUVIEN. Interest on outstanding borrowings under the term loan is payable at the greater of 10.90%, or 7.65% plus the prime rate per annum. The term loan, which matures on May 1, 2018, provides for interest only payments thru November 30, 2015, followed by 30 equal monthly payments of principal and interest. The interest-only period may be extended to May 31, 2017, followed by 12 equal monthly payments of principal and interest, if certain revenue thresholds are reached.

Alimera Sciences, pSivida's Iluvien Obtains US FDA's Approval for DME

Alimera Sciences (US) has announced the US FDA's approval of Iluvien (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular oedema/edema (DME) in patients who failed to demonstrate a clinically significant rise in intraocular pressure with corticosteroids therapy. The regulatory approval was based on data that showed 28.7% of patients treated with Iluvien demonstrated an improvement in best-corrected visual acuity at month 24 that was maintained to the end of the trial at 36 months. Alimera anticipates launching the drug in the market in the first quarter of 2015. Iluvien was licensed to Alimera from pSivida Corp. (US) under a 2008 agreement.

Alimera Sciences, Inc. - Special Call

To discuss the ILUVIEN approval

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALIM:US $4.76 USD -0.01

ALIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALIM.
View Industry Companies
 

Industry Analysis

ALIM

Industry Average

Valuation ALIM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALIMERA SCIENCES INC, please visit www.alimerasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.